Uncategorized

Mesoblast to File Biologics License Application for Ryoncil® FDA Approval Next Week

Mesoblast Limited, global leader in allogeneic cellular medicines for inflammatory diseases, confirmed that it will file its Biologics License Application for approval of Ryoncil® in the treatment of children with steroid-refractory acute graft versus host disease with the U.S. Food and Drug Administration next week.

Mesoblast to File Biologics License Application for Ryoncil® FDA Approval Next Week Read More »

Biophytis Presented its Phase 2-3 COVA Study Results in Severe Forms of Covid-19 at the WCID in Paris

Biophytis SA, a clinical-stage biotechnology company specialized in the development of therapeutics for age-related diseases, presented the roll-out and results of its phase 2/3 COVA study in the treatment of severe forms of Covid-19 at the 6th edition of the World Congress on Infectious Diseases, held from June 24 to 26, 2024 in Paris, France.

Biophytis Presented its Phase 2-3 COVA Study Results in Severe Forms of Covid-19 at the WCID in Paris Read More »

SCG Cell Therapy Announces FDA IND Clearance of SCG142, a next-generation HPV-specific TCR T cell therapy for patients with HPV-associated solid tumors

SCG Cell Therapy Pte Ltd announced that U.S. Food and Drug Administration has approved the Investigational New Drug application to initiate Phase 1/2 clinical trial for SCG142, a novel next-generation human papillomavirus E7-specific T-cell receptor-engineered T cell therapy for patients with HPV-associated solid tumors.

SCG Cell Therapy Announces FDA IND Clearance of SCG142, a next-generation HPV-specific TCR T cell therapy for patients with HPV-associated solid tumors Read More »

Scroll to Top